Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)
Avalo Therapeutics (AVTX) reported Common Equity of $448.66 million for Q2 2026, up 329.0% from $104.57 million a year earlier and up 556.7% from the prior quarter.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Common Equity (2014 - 2026) Analysis & Trends
At the end of FY2025, Avalo Therapeutics posted Common Equity of $83.05 million, down 37.6% from FY2024.
- Common Equity has a five-year compound annual growth rate of 27.6% (FY2020 to FY2025).
- By year, Common Equity came in at $133.03 million in FY2024, $7.3 million in FY2023, -$10.92 million in FY2022 and $23.08 million in FY2021 (-6.0%).
- The Q2 2026 figure ranks as the highest quarterly Common Equity in data going back to Q4 2014.
- Year over year, Common Equity gained in three of the last five quarters, with growth averaging 125.0%.
- The high point for year-over-year Common Equity in five years was Q3 2025 (growth of 334.4%); the low point was Q1 2022 (a decline of 80.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $68.32 million (Q1 2026), $83.05 million (Q4 2025) and $91.55 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Avalo Therapeutics | 657.52 Mn | 657.52 Mn | - | 448.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 448.66 Mn |
| Mar 31, 2026 | 68.32 Mn |
| Dec 31, 2025 | 83.05 Mn |
| Sep 30, 2025 | 91.55 Mn |
| Jun 30, 2025 | 104.57 Mn |
| Mar 31, 2025 | 122.62 Mn |
| Dec 31, 2024 | 133.03 Mn |
| Sep 30, 2024 | 21.08 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -112.54 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Sep 30, 2023 | 14.70 Mn |
| Jun 30, 2023 | -6.97 Mn |
| Mar 31, 2023 | -6.27 Mn |
| Dec 31, 2022 | -10.92 Mn |
| Sep 30, 2022 | -2.03 Mn |
| Jun 30, 2022 | -5.95 Mn |
| Mar 31, 2022 | 6.34 Mn |
| Dec 31, 2021 | 23.08 Mn |
| Sep 30, 2021 | 40.31 Mn |
API Access
Avalo Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=AVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();